The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations / 癌症
Chinese Journal of Cancer
; (12): 136-140, 2013.
Article
in En
| WPRIM
| ID: wpr-295826
Responsible library:
WPRO
ABSTRACT
For patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer, the relationship between the dose or duration of treatment with tyrosine kinase inhibitor (TKI) and overall survival remains unclear. Here, we analyzed clinical data of 39 patients who were diagnosed with EGFR mutation-positive non-small cell lung cancer and treated with TKI, but subsequently died. Several parameters were measured in this study overall survival; first, second, and overall TKI therapy durations; first TKI intensity (actual dose/normal dose); and TKI rate (overall TKI therapy duration/overall survival). The response rate to TKI therapy was 50%, and the median survival was 553 days. After TKI therapy failed, 38.5% patients were re-challenged with TKI. We observed a moderate relationship [r = 0.534, 95% confidential interval (CI) = 0.263 to 0.727, P < 0.001] between overall TKI therapy duration and overall survival. However, we found no relationship between overall survival and first TKI intensity (r = 0.073, 95% CI = -0.380 to 0.247, P = 0.657) or TKI rate (r = 0.0345, 95% CI = -0.284 to 0.346, P = 0.835). Non-small cell lung cancer patients with mutation-positive tumors remained on TKI therapy for, on average, 33% of the overall survival time. These findings suggest that patients with EGFR mutation-positive tumors should not stick to using TKIs.
Full text:
1
Index:
WPRIM
Main subject:
Quinazolines
/
Protein-Tyrosine Kinases
/
Survival Rate
/
Carcinoma, Non-Small-Cell Lung
/
Therapeutic Uses
/
Protein Kinase Inhibitors
/
Dose-Response Relationship, Drug
/
Drug Therapy
/
ErbB Receptors
/
Erlotinib Hydrochloride
Limits:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Language:
En
Journal:
Chinese Journal of Cancer
Year:
2013
Type:
Article